Amylyx co-CEOs Josh Cohen (L) and Justin Klee
Amylyx's ALS drug sales beat Wall Street expectations in first full quarter
The sales numbers are in for Amylyx’s first full quarter as a commercial-stage biotech, and by and large they beat the Street’s expectations.
Amylyx’s ALS …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
